Biotech Catalyst Daily Pro
Ticker-filtered catalyst intelligence for buy-side analysts and generalist PMs. Your tickers, your therapeutic areas, with readout prep 2 weeks before every binary event.
Who uses Pro
Buy-side Analyst
Watchlist of 30 small-cap biotech tickers. Gets readout prep packs 2 weeks before every binary event; sees CT.gov protocol-amendment alerts the day they land.
Generalist PM
Therapeutic areas: oncology + metabolic. Gets AdCom prep packs 48h out for any drug in those indications, never surprised by an Advisory Committee vote.
Pharma BD
Watches competitor pipelines across oncology + rare disease. Uses daily digest as an early-warning system for licensing targets before they go public.
Sell-side Associate
Covers 12 biotechs across multiple analysts. Uses FDA decision alerts (within 15 min) to beat the desk on client-facing note drafts.
Ticker-filtered daily digest
Tell us your watchlist (tickers + therapeutic areas). The daily Pro briefing covers only the catalysts, deal tape, and clinical readouts tied to names you hold or watch. No more scrolling past tickers you don’t care about to find the four that matter to your book.
Readout prep packs (2 weeks out)
When a Phase 2/3 readout on a watched name is 2 weeks away, you get a dedicated prep pack: registered protocol summary, powering calculation, prior-phase reconciliation, placebo-prior expectations, endpoint scrutiny, competitor comparables. What you’d pull together yourself in three hours — already done.
Clinical trial watchlist alerts
Follow specific NCT IDs. When a protocol amendment hits, primary completion date moves, or enrollment update drops on ClinicalTrials.gov, you get the delta + what it likely signals. Protocol amendments in the last 6 months before a readout are often the tell.
AdCom briefing packs (48h before)
Two days before every scheduled FDA Advisory Committee meeting, you get a distilled briefing: sponsor materials + FDA staff review + analyst consensus + historical AdCom base rates for the indication. The brief every analyst wishes they had but rarely finishes in time.
FDA decision instant alerts
Within 15 minutes of an FDA approval, CRL, or AdCom vote landing for a watched name, you get an email with the decision, the likely near-term impact framing, and the next-step questions worth asking. Get out in front of price action.
Sample readout prep pack — 14 days before Phase 3 data
ONCO-7 (fictional ticker) — pembrolizumab-combo in first-line NSCLC with bioMRK-high expression
Primary endpoint read: OS at 24-month median follow-up. Trial powered for 25% HR improvement; anything above HR 0.80 is a commercial win, HR 0.75 or lower repositions the standard of care. Street consensus: HR 0.78.
Placebo prior: Three comparable Phase 3 combos in this indication since 2022 delivered HRs 0.72, 0.85, 0.81. The 0.85 was driven by lower-than-expected PD-L1 subset response; watch the bioMRK cut on readout day.
Safety concerns to monitor: Class-wide pneumonitis rate in the combo arm — if >7% Grade 3+, expect label restrictions even on an OS win. Discontinuation rate above 18% would hurt the commercial pitch vs. monotherapy.
Subgroup red flags: Pre-specified subgroups — PD-L1 TPS ≥50%, age <65, smoking history. Surprise responder subgroups (e.g., post-hoc liver-metastases win) are a low-signal signal; treat with skepticism.
Key questions to ask on the call: (1) Was OS significance maintained in the ITT after censoring crossover? (2) How does the bioMRK-negative arm compare? (3) What is the projected peak commercial opportunity at the approved label?
This is a representative example. Each actual prep pack is synthesized from the real trial’s public ClinicalTrials.gov record + historical comparables in the indication.
Free vs. Pro
| Feature | Free | Pro — $49/mo |
|---|---|---|
| Daily biotech catalyst briefing | Full sector | Your watchlist only |
| Therapeutic-area filter | — | ✓ |
| Clinical trial watchlist (ClinicalTrials.gov) | — | Unlimited NCT IDs |
| Readout prep packs (2 weeks before Phase 2/3) | — | ✓ |
| AdCom briefing packs (48h before meetings) | — | ✓ |
| FDA decision alerts (≤ 15 min) | — | ✓ |
| Free guide library (8 PDFs, all audiences) | ✓ | ✓ |
| Setup time | 30 sec | 90 sec after checkout |
7-day free trial · Cancel anytime · Founding rate locked for life (first 100 subs)
Use promo code FOUNDING_BIOTECH_50 at checkout for 50% off your first year (limited to first 100).
Questions
How is this different from the free Biotech Catalyst Daily?
Free covers the whole sector every morning. Pro covers only the catalysts on your watchlist, with added readout prep 2 weeks before each binary event, AdCom briefing packs 48 hours before committee meetings, and instant FDA-decision alerts. If you manage a book with biotech exposure, Pro is built for your process.
How many tickers can I watch?
No hard limit, but 20–40 is the typical active watchlist. We’ll flag if you exceed ~100 (at which point your briefing becomes the free version again).
Do you cover ex-US biotech (Europe, China)?
Yes for trials, deals, and regulatory decisions. Primary focus is FDA-regulated drugs; we cover EMA (CHMP opinions) and NMPA (China) for material moves on US-listed names. Hong Kong and European exchanges: partial, not comprehensive.
How soon are readout prep packs delivered?
Targeting 14 days before the readout window opens. For 1H/2H readout guidance with no specific date, we work with the sponsor’s stated guidance and update as it narrows.
Can I cancel anytime?
Yes. One-click in the Stripe customer portal. Pro features stay active through the end of the current billing period; no partial refunds, no more charges after cancel.
Who writes this?
Ryan Burns (Burns Media) with AI-assisted drafting and human editing. Biotech-specific domain review on all clinical/regulatory claims. We cite sources, flag uncertainty, and don’t recommend trades.
Do you have a sample?
The free Biotech Catalyst Daily shows you the writing style. Pro applies the same voice to your watchlist plus the prep packs and alerts. Subscribe free first if you want to evaluate.
Not ready for Pro?
Subscribe to the free Biotech Catalyst Daily — same editorial voice, full sector coverage, unlimited free.